AR056328A1 - TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN - Google Patents

TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN

Info

Publication number
AR056328A1
AR056328A1 ARP060101669A ARP060101669A AR056328A1 AR 056328 A1 AR056328 A1 AR 056328A1 AR P060101669 A ARP060101669 A AR P060101669A AR P060101669 A ARP060101669 A AR P060101669A AR 056328 A1 AR056328 A1 AR 056328A1
Authority
AR
Argentina
Prior art keywords
compositions
micronized
preparation
useful
contain
Prior art date
Application number
ARP060101669A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056328A1 publication Critical patent/AR056328A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composiciones farmacéuticas, que contienen tanaproget micronizado. Las composiciones también pueden contener celulosa microcristalina, croscarmelosa sodica, lactosa anhidra, estearato magnésico, edetato cálcico disodico hidratado micronizado, y tiosulfato sodico pentahidratado micronizado. Las composiciones son utiles en la contracepcion y en la terapia de reemplazo hormonal y en el tratamiento y/o prevencion de fibroides miometriales uterinos, hipertrofia prostática benigna, enfermedad neoplásica benigna y maligna, sangrado disfuncional, leiomioma uterino, endometriosis, síndrome de ovario policístico, y carcinomas y adenocarcinomas de la pituitaria, endometrio, rinon, ovario, mama, colon, y prostata y otros tumores dependientes de hormonas y en la preparacion de medicacion utiles para los mismos. Los usos adicionales incluyen la estimulacion de la ingesta de alimentos.
ARP060101669A 2005-04-28 2006-04-26 TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN AR056328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67555005P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR056328A1 true AR056328A1 (es) 2007-10-03

Family

ID=37023145

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101669A AR056328A1 (es) 2005-04-28 2006-04-26 TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN

Country Status (19)

Country Link
US (4) US7767668B2 (es)
EP (1) EP1896034B8 (es)
JP (2) JP5149159B2 (es)
CN (1) CN101166532B (es)
AR (1) AR056328A1 (es)
AT (1) ATE460937T1 (es)
AU (1) AU2006241113B2 (es)
BR (1) BRPI0610437A2 (es)
CA (1) CA2603806C (es)
CY (1) CY1110009T1 (es)
DE (1) DE602006012972D1 (es)
DK (1) DK1896034T3 (es)
ES (1) ES2340610T3 (es)
MX (1) MX2007013465A (es)
PL (1) PL1896034T3 (es)
PT (1) PT1896034E (es)
SI (1) SI1896034T1 (es)
TW (1) TW200716129A (es)
WO (1) WO2006116514A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
BRPI0610438A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
TW200716129A (en) * 2005-04-28 2007-05-01 Wyeth Corp Micronized tanaproget, compositions, and methods of preparing the same
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
DE602006013114D1 (de) 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
HN2006020928A (es) 2005-06-09 2011-02-16 Wyeth Corp "composiciones de tanaproget que contienen etinil estradiol"
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9040825B2 (en) * 2007-11-13 2015-05-26 Southwire Company, Llc Conductors and metal-covered cable with coded information and method of applying coded information
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
EP3000467B1 (en) 2009-04-06 2023-03-01 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
HUE046606T2 (hu) * 2009-11-09 2020-03-30 Wyeth Llc Neratinib maleát tabletta formái
CN102724962B (zh) 2009-11-09 2017-05-17 惠氏有限责任公司 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
EP2512455B8 (en) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
MX2015016038A (es) 2013-05-21 2016-03-21 Predictive Therapheutics Llc Agente terapéutico y método de uso.
GB201318394D0 (en) * 2013-10-17 2013-12-04 Univ Edinburgh Composition
CN117835971A (zh) 2021-08-25 2024-04-05 巴斯夫欧洲公司 直接压片用辅料组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038108T2 (de) * 1999-05-04 2009-02-12 Wyeth Cyclothiocarbamatderivate als progesteron-rezeptormodulatoren
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
US7192956B2 (en) * 2002-06-25 2007-03-20 Wyeth Methods of treating hormone-related conditions using cyclothiocarbamate derivatives
KR20050013627A (ko) * 2002-06-25 2005-02-04 와이어쓰 Ｐｒ 조절제로서의 사이클로티오카바메이트 유도체 및피부 질환을 치료하기 위한 이의 용도
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
PL1756095T3 (pl) 2004-04-27 2008-10-31 Wyeth Corp Cyjanopirole zawierające cykliczne karbaminianowe i tiokarbaminianowe biaryle oraz sposoby ich wytwarzania
PE20060331A1 (es) 2004-04-27 2006-05-16 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
BRPI0512991A (pt) * 2004-07-07 2008-04-22 Wyeth Corp uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US7569679B2 (en) * 2004-08-13 2009-08-04 Wyeth Tanaproget derivatives, metabolites, and uses thereof
JP2008510722A (ja) * 2004-08-20 2008-04-10 ワイス プロゲステロン受容体構造
BRPI0610438A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
GT200600173A (es) * 2005-04-28 2006-11-22 Forma purificada de tranaproget
DE602006013114D1 (de) 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
TW200716129A (en) * 2005-04-28 2007-05-01 Wyeth Corp Micronized tanaproget, compositions, and methods of preparing the same
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
HN2006020928A (es) * 2005-06-09 2011-02-16 Wyeth Corp "composiciones de tanaproget que contienen etinil estradiol"

Also Published As

Publication number Publication date
ES2340610T3 (es) 2010-06-07
SI1896034T1 (sl) 2010-07-30
US20100189789A1 (en) 2010-07-29
CY1110009T1 (el) 2015-01-14
JP2008539256A (ja) 2008-11-13
EP1896034B8 (en) 2010-05-19
US8450312B2 (en) 2013-05-28
JP2013006840A (ja) 2013-01-10
CA2603806A1 (en) 2006-11-02
US20130251807A1 (en) 2013-09-26
PL1896034T3 (pl) 2010-07-30
WO2006116514A2 (en) 2006-11-02
MX2007013465A (es) 2008-01-21
TW200716129A (en) 2007-05-01
US20140328925A1 (en) 2014-11-06
BRPI0610437A2 (pt) 2012-10-23
CA2603806C (en) 2013-03-19
AU2006241113A1 (en) 2006-11-02
US20060246135A1 (en) 2006-11-02
CN101166532A (zh) 2008-04-23
ATE460937T1 (de) 2010-04-15
EP1896034A2 (en) 2008-03-12
WO2006116514A3 (en) 2006-12-14
CN101166532B (zh) 2011-06-22
EP1896034B1 (en) 2010-03-17
JP5149159B2 (ja) 2013-02-20
PT1896034E (pt) 2010-05-06
AU2006241113B2 (en) 2011-08-18
US8772271B2 (en) 2014-07-08
US7767668B2 (en) 2010-08-03
DE602006012972D1 (de) 2010-04-29
DK1896034T3 (da) 2010-05-17

Similar Documents

Publication Publication Date Title
AR056328A1 (es) TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
TW200716621A (en) Polymorph form II of tanaproget
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
TW200731969A (en) Use of progesterone receptor modulators
CY1125254T1 (el) Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης
CY1118209T1 (el) Αντισωματα εξουδετερωσης υποδοχεα προλακτινης και θεραπευτικη χρηση αυτων
CR9644A (es) Agonistas del receptor de la hormonatiroidea
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
MX338217B (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-a rilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades.
AU2003255820A8 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
EA201491344A1 (ru) Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
DE602005019905D1 (de) -modulatoren
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
PA8771801A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
DOP2006000150A (es) Modulares no esteroides de receptores de progesterona
DOP2006000147A (es) Uso de modulares no esteroides de receptores de progesterona.
DOP2006000148A (es) Moduladores no esteroides de receptores de progesterona
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
PL1809602T3 (pl) Pochodne indolowe przydatne jako modulatory receptora progesteronu
JP2009535428A5 (es)
TH58099B (th) การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
AR023854A1 (es) Uso de derivados de indolina y equipo farmaceutico para regimenes ciclicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal